Juno Therapeutics is seeking to change the protocol for the Phase II ROCKET clinical trial of its acute
lymphoblastic leukemia candidate JCAR015, which the FDA has placed on clinical hold following the deaths of three patients, two of them last week.
Juno Therapeutics will resume its Phase II ROCKET clinical trial of its acute
lymphoblastic leukemia candidate JCAR015 following the FDA's lifting of a partial clinical hold imposed last week following the deaths of three patients.
Not exact matches
JCAR015 is a CD19 - directed chimeric antigen receptor technology (CAR - T) product
candidate that has been under study in ROCKET in adult patients with relapsed or refractory B - cell acute
lymphoblastic leukemia.